Who are the key players in the oncologycancer drugs market?

Some of the key players are Companies, Astellas Pharma Inc, Amgen Inc, Others.

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2027

Q: How big is the oncologycancer drugs market?

The global oncology drugs market was valued at 128352 million in 2019 and is projected to reach 222380 million by 2027 registering a CAGR of 7.4.Cancer is the uncontrolled growth of abnormal cells in the body.

Code: ALLI-Auto-2O5

Report

March 2021

Pages:242

Allied Market Research

Description

Table of Content

Tables & Figures

FEATURED COMPANIES

Companies

Astellas Pharma Inc

Amgen Inc

Oncology/Cancer Drugs Market Statistics 2027

The global oncology drugs market was valued at $128,352 million in 2019, and is projected to reach $222,380 million by 2027, registering a CAGR of 7.4%. Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body’s normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global oncology/cancer drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis for the period of 2019–2027 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market by components helps to understand the various types of instruments used across geographies.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these regions.
Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
Extensive analysis of the market is conducted by closely following key product positioning, and monitoring the top contenders within the market framework.

KEY MARKET SEGMENTS

By Drug Class Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By Indication

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe

Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East and Africa

FEATURED COMPANIES

Companies

Astellas Pharma Inc

Amgen Inc

CHAPTER 1:INTRODUCTION

1.1.Report description

1.2.Key benefits for stakeholders

1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.2.2.Top winning strategies, 2019

3.3.Top player positioning, 2019

3.4.Porter’s five forces analysis

3.5.Clinical trials

3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidence of cancer across the globe

3.6.1.2.Surge in global geriatric population

3.6.1.3.Increase in government expenditure on healthcare

3.6.2.Restraints

3.6.2.1.Adverse effects associated with the use cancer drugs

3.6.3.Opportunities

3.6.3.1.High growth potential in untapped emerging economies

3.6.3.2.Increase in number of pipeline drugs

3.6.4.Impact analysis

3.7.COVID-19 impact analysis on oncology/ cancer drugs market

CHAPTER 4:ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Chemotherapy

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Targeted therapy

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

4.4.Immunotherapy (biologic therapy)

4.4.1.Key market trends, growth factors, and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis, by country

4.5.Hormonal therapy

4.5.1.Key market trends, growth factors, and opportunities

4.5.2.Market size and forecast, by region

4.5.3.Market analysis, by country

CHAPTER 5:ONCOLOGY/ONCOLOGY/CANCER DRUGS MARKET, BY INDICATIION

5.1.Overview

5.1.1.Market size and forecast

5.2.Lung cancer

5.2.1.Market size and forecast, by region

5.2.2.Market share analysis, by country

5.3.Stomach cancer

5.3.1.Market size and forecast, by region

5.3.2.Market analysis, by country

5.4.Colorectal cancer

5.4.1.Market size and forecast, by region

5.4.2.Market share analysis, by country

5.5.Breast cancer

5.5.1.Market size and forecast, by region

5.5.2.Market share analysis, by country

5.6.Prostate cancer

5.6.1.Market size and forecast, by region

5.6.2.Market share analysis, by country

5.7.Liver cancer

5.7.1.Market size and forecast, by region

5.7.2.Market share analysis, by country

5.8.Esophagus cancer

5.8.1.Market size and forecast, by region

5.8.2.Market share analysis, by country

5.9.Cervical cancer

5.9.1.Market size and forecast, by region

5.9.2.Market share analysis, by country

5.10.Kidney cancer

5.10.1.Market size and forecast, by region

5.10.2.Market share analysis, by country

5.11.Bladder cancer

5.11.1.Market size and forecast, by region

5.11.2.Market share analysis, by country

5.12.Other cancers

5.12.1.Market size and forecast, by region

5.12.2.Market share analysis, by country

CHAPTER 6:ONCOLOGY/CANCER DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities

6.2.2.Market size and forecast, by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. Oncology/Cancer Drugs Market, by drug class type

6.2.2.1.2.U.S. oncology/Cancer Drugs Market, by indication

6.2.2.2.Canada

6.2.2.2.1.Canada oncology/cancer drugs market, by drug class type

6.2.2.2.2.Canada oncology/cancer drugs market, by indication

6.2.2.3.Mexico

6.2.2.3.1.Mexico oncology/cancer drugs market, by drug class type

6.2.2.3.2.Mexico Oncology/Cancer Drugs Market, by indication

6.2.3.Market size and forecast, by drug class type

6.2.4.Market size and forecast, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities

6.3.2.Market size and forecast, by country

6.3.2.1.Germany

6.3.2.1.1.Germany oncology/cancer drugs market, by drug class type

6.3.2.1.2.Germany oncology/cancer drugs market, by indication

6.3.2.2.France

6.3.2.2.1.France oncology/cancer drugs market, by drug class type

6.3.2.2.2.France oncology/cancer drugs market, by indication

6.3.2.3.UK

6.3.2.3.1.UK oncology/cancer drugs market, by drug class type

6.3.2.3.2.UK oncology/cancer drugs market, by indication

6.3.2.4.Italy

6.3.2.4.1.Italy oncology/cancer drugs market, by drug class type

6.3.2.4.2.Italy oncology/cancer drugs market, by indication

6.3.2.5.Spain

6.3.2.5.1.Spain oncology/cancer drugs market, by drug class type

6.3.2.5.2.Spain oncology/cancer drugs market, by indication

6.3.2.6.Rest of Europe

6.3.2.6.1.Rest of Europe oncology/cancer drugs market, by drug class type

6.3.2.6.2.Rest of Europe oncology/cancer drugs market, by indication

6.3.3.Market size and forecast, by drug class type

6.3.4.Market size and forecast, by indication

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities

6.4.2.Market size and forecast, by country

6.4.2.1.Japan

6.4.2.1.1.Japan oncology/cancer drugs market, by drug class type

6.4.2.1.2.Japan oncology/cancer drugs market, by indication

6.4.2.2.China

6.4.2.2.1.China oncology/cancer drugs market, by drug class type

6.4.2.2.2.China oncology/cancer drugs market, by indication

6.4.2.3.Australia

6.4.2.3.1.Australia oncology/cancer drugs market, by drug class type

6.4.2.3.2.Australia oncology/cancer drugs market, by indication

6.4.2.4.India

6.4.2.4.1.India cancer oncology/cancer market, by drug class type

6.4.2.4.2.India oncology/cancer drugs market, by indication

6.4.2.5.South Korea

6.4.2.5.1.South Korea oncology/cancer drugs market, by drug class type

6.4.2.5.2.South Korea oncology/cancer drugs market, by indication

6.4.2.6.Rest of Asia-Pacific

6.4.2.6.1.Rest of Asia-Pacific oncology/cancer drugs market, by drug class type

6.4.2.6.2.Rest of Asia-Pacific oncology/cancer drugs market, by indication

6.4.3.Market size and forecast, by drug class type

6.4.4.Market size and forecast, by indication

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities

6.5.2.Market size and forecast, by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil oncology/cancer drugs market, by drug class type

6.5.2.1.2.Brazil oncology/cancer drugs market, by indication

6.5.2.2.Saudi Arabia

6.5.2.2.1.Saudi Arabia oncology/cancer drugs market, by drug class type

6.5.2.2.2.Saudi Arabia oncology/cancer drugs market, by indication

6.5.2.3.South Africa

6.5.2.3.1.South Africa oncology/cancer drugs market, by drug class type

6.5.2.3.2.South Africa oncology/cancer drugs market, by indication

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA oncology/cancer drugs market, by drug class type

6.5.2.4.2.Rest of LAMEA cancer drugs market, by indication

6.5.3.Market size and forecast, by drug class type

6.5.4.Market size and forecast, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBVIE INC.

7.1.1.Company overview

7.1.2.Company snapshot

7.1.3.Operating business segments

7.1.4.Product portfolio

7.1.5.Business performance

7.1.6.Key strategic moves and developments

7.2.AMGEN INC.

7.2.1.Company overview

7.2.2.Company snapshot

7.2.3.Operating business segments

7.2.4.Product portfolio

7.2.5.Business performance

7.2.6.Key strategic moves and developments

7.3.ASTELLAS PHARMA INC.

7.3.1.Company overview

7.3.2.Company snapshot

7.3.3.Operating business segments

7.3.4.Product Portfolio

7.3.5.Business performance

7.4.ASTRAZENECA PLC.

7.4.1.Company overview

7.4.2.Company snapshot

7.4.3.Operating business segments

7.4.4.Product Portfolio

7.4.5.Business performance

7.4.6.Key strategic moves and developments

7.5.BRISTOL-MYERS SQUIBB COMPANY

7.5.1.Company overview

7.5.2.Company snapshot

7.5.3.Operating business segments

7.5.4.Product Portfolio

7.5.5.Business performance

7.5.6.Key strategic moves and developments

7.6.F. HOFFMANN-LA ROCHE LTD.

7.6.1.Company overview

7.6.2.Company snapshot

7.6.3.Operating business segments

7.6.4.Product portfolio

7.6.5.Business performance.

7.6.6.Key strategic moves and developments

7.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)

7.7.1.Company overview

7.7.2.Company snapshot

7.7.3.Operating business segments

7.7.4.Product portfolio

7.7.5.Business performance

7.8.MERCK & CO., INC.

7.8.1.Company overview

7.8.2.Company snapshot

7.8.3.Operating business segments

7.8.4.Product Portfolio

7.8.5.Business performance

7.8.6.Key strategic moves and developments

7.9.NOVARTIS INTERNATIONAL AG (SANDOZ)

7.9.1.Company overview

7.9.2.Company snapshot

7.9.3.Operating business segments

7.9.4.Product portfolio

7.9.5.Business performance

7.9.6.Key strategic moves and developments

7.10.PFIZER INC.

7.10.1.Company overview

7.10.2.Company snapshot

7.10.3.Operating business segments

7.10.4.Product portfolio

7.10.5.Business performanc

FEATURED COMPANIES

Companies

Astellas Pharma Inc

Amgen Inc

LIST OF TABLES

TABLE 01.COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017–2021

TABLE 02.ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)

TABLE 03.ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2019–2027 ($MILLION)

TABLE 04.ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2019–2027 ($MILLION)

TABLE 05.ONCOLOGY/CANCER DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY REGION, 2019–2027 ($MILLION)

TABLE 06.ONCOLOGY/CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2019–2027 ($MILLION)

TABLE 07.ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027($MILLION)

TABLE 08.ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2019–2027($MILLION)

TABLE 09.ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2019–2027($MILLION)

TABLE 10.ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2027($MILLION)

TABLE 11.ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2019–2027($MILLION)

TABLE 12.ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027($MILLION)

TABLE 13.ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2019–2027($MILLION)

TABLE 14.ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 2019–2027($MILLION)

TABLE 15.ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2019–2027($MILLION)

TABLE 16.ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2019–2027($MILLION)

TABLE 17.ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2019–2027($MILLION)

TABLE 18.ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 2019–2027 ($MILLION)

TABLE 19.ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)

TABLE 20.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 21.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 22.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 23.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 24.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 25.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 26.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 27.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)

TABLE 28.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 29.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 30.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 33.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 34.UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 35.UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 36.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 37.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 38.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 39.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 40.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 41.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 42.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)

TABLE 43.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 44.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 45.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 46.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 47.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 48.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 49.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 50.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 51.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 52.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 53.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 54.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 55.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 56.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 57.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)

TABLE 58.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 59.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 60.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 61.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 62.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 63.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 64.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 65.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 66.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027

TABLE 67.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027

TABLE 68.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)

TABLE 69.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 70.ABBVIE: COMPANY SNAPSHOT

TABLE 71.ABBVIE: OPERATING SEGMENT

TABLE 72.ABBVIE: PRODUCT PORTFOLIO

TABLE 73.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 74.AMGEN: COMPANY SNAPSHOT

TABLE 75.AMGEN: OPERATING SEGMENT

TABLE 76.AMGEN: PRODUCT PORTFOLIO

TABLE 77.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 78.ASTELLAS: COMPANY SNAPSHOT

TABLE 79.ASTELLAS: PRODUCT PORTFOLIO

TABLE 80.ASTRAZENECA: COMPANY SNAPSHOT

TABLE 81.ASTRAZENECA: OPERATING SEGMENTS

TABLE 82.ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 83.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 84.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 85.ROCHE: COMPANY SNAPSHOT

TABLE 86.ROCHE: OPERATING SEGMENTS

TABLE 87.ROCHE: PRODUCT PORTFOLIO

TABLE 88.J&J: COMPANY SNAPSHOT

TABLE 89.J&J: OPERATING SEGMENTS

TABLE 90.J&J: PRODUCT TYPE PORTFOLIO

TABLE 91.MERCK: COMPANY SNAPSHOT

TABLE 92.MERCK: OPERATING SEGMENTS

TABLE 93.MERCK: PRODUCT PORTFOLIO

TABLE 94.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 95.NOVARTIS: OPERATING SEGMENTS

TABLE 96.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 97.PFIZER: COMPANY SNAPSHOT

TABLE 98.PFIZER: OPERATING SEGMENTS

TABLE 99.PFIZER: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01.GLOBAL ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

FIGURE 02.TOP INVESTMENT POCKETS

FIGURE 03.TOP WINNING STRATEGIES, 2017–2019

FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2017–2019

FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2019

FIGURE 06.TOP PLAYER POSITIONING, 2019

FIGURE 07.MODERATE BARGANING POWER OF BUYERS

FIGURE 08.HIGH BARGANING POWER OF SUPPLIERS

FIGURE 09.MODERATE THREAT OF SUBSTITUTION

FIGURE 10.MODERATE THREAT OF NEW ENTRANTS

FIGURE 11.HIGH COMPETITIVE RIVALRY

FIGURE 12.IMPACT ANALYSIS

FIGURE 13.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR CHEMOTHERAPY BY COUNTRY, 2019–2027 (%)

FIGURE 14.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR TARGETED THERAPY BY COUNTRY, 2019–2027 (%)

FIGURE 15.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR IMMUNOTHERAPY (BIOLOGIC THERAPY) BY COUNTRY, 2019–2027 (%)

FIGURE 16.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR HORMONAL THERAPY BY COUNTRY, 2019–2027 (%)

FIGURE 17.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2019 & 2027

FIGURE 18.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2019 & 2027

FIGURE 19.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019 & 2027

FIGURE 20.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2019 & 2027

FIGURE 21.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2019 & 2027

FIGURE 22.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2019 & 2027

FIGURE 23.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2019 & 2027

FIGURE 24.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2019 & 2027

FIGURE 25.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2019 & 2027

FIGURE 26.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2019 & 2027

FIGURE 27.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2019 & 2027

FIGURE 28.U.S. ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 29.CANADA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 30.MEXICO ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 33.UK ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 34.ITALY ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 35.SPAIN ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 36.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 37.JAPAN ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 38.CHINA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 39.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 40.INDIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 41.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 42.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 43.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 44.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 45.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 46.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)

FIGURE 47.ABBVIE: NET SALES, 2017–2019 ($MILLION)

FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2019(%)

FIGURE 49.AMGEN: NET SALES, 2017–2019 ($MILLION)

FIGURE 50.AMGEN: REVENUE SHARE BY REGION, 2019(%)

FIGURE 51.ASTELLAS: SALES, 2017–2019 ($MILLION)

FIGURE 52.ASTRAZENECA: REVENUE, 2018–2020 ($MILLION)

FIGURE 53.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 54.REVENUE, 2018–2020 ($MILLION)

FIGURE 55.BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 56.ROCHE: NET SALES, 2017–2019 ($MILLION)

FIGURE 57.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)

FIGURE 58.ROCHE: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 59.J&J: REVENUE, 2018–2020 ($MILLION)

FIGURE 60.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)

FIGURE 61.J&J: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 62.MERCK: NET SALES, 2017–2019 ($MILLION)

FIGURE 63.MERCK: NET SALES BY SEGMENT, 2019 (%)

FIGURE 64.MERCK: NET SALES BY REGION, 2019 (%)

FIGURE 65.NOVARTIS: NET SALES, 2018–2020 ($MILLION)

FIGURE 66.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)

FIGURE 67.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 68.PFIZER: NET SALES, 2017–2019 ($MILLION)

FIGURE 69.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 70.PFIZER: REVENUE SHARE, BY REGION, 2019 (%

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$6168

This license allows only one user(purchaser of the report) to access the PDF.

Multi User

Electronic (PDF)

$6929

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9663

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Data Pack/Excel

Electronic (Excel)

$4125

This license allows users/teams to use the numbers mentioned in the Excel sheet within an organisation

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Published Date: March 2021

Report Code: ALLI-Auto-2O5

FEATURED COMPANIES

KEY BENEFITS FOR STAKEHOLDERS

KEY MARKET SEGMENTS

FEATURED COMPANIES

FEATURED COMPANIES

HAVE A QUERY?

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-4O8609

Wed Apr 17 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-25I8231

Wed Apr 17 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-2M4266

Wed Apr 17 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-38E8328

Wed Apr 17 00:00:00 UTC 2024

Support Contacts

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

POLICIES

THE COMPANY

CUSTOMER SUPPORT

OUR PRODUCTS

POLICES

Copyright © 2018 Valuates.com. All Rights Reserved.

Sitemap - Privacy Policy - Terms & Conditions